Bluejay Diagnostics Inc (BJDX) USD0.0001

Sell:$3.31Buy:$3.66$0.18 (5.01%)

Prices delayed by at least 15 minutes
Sell:$3.31
Buy:$3.66
Change:$0.18 (5.01%)
Prices delayed by at least 15 minutes
Sell:$3.31
Buy:$3.66
Change:$0.18 (5.01%)
Prices delayed by at least 15 minutes

Company Information

About this company

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.

Key people

Neil Dey
President, Chief Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
Jason Cook
Chief Technology Officer
Douglas Clark Wurth
Independent Chairman of the Board
Svetlana Dey
Director
Donald R. Chase
Independent Director
Gary Gemignani
Independent Director
Fred S. Zeidman
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US0956335097
  • Market cap
    $1.98m
  • Employees
    10
  • Shares in issue
    552,854.00
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.